Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Vatanidipine hydrochloride: a new long-lasting antihypertensive agent
Autore:
Matsumura, Y; Hayashi, K;
Indirizzi:
Osaka Univ Pharmaceut Sci, Dept Pharmacol, Takatsuki, Osaka 5691094, JapanOsaka Univ Pharmaceut Sci Takatsuki Osaka Japan 5691094 ka 5691094, Japan Welfide Corp, Div Pharmaceut Res, Hirakata, Osaka 5731153, Japan Welfide Corp Hirakata Osaka Japan 5731153 Hirakata, Osaka 5731153, Japan
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 1, volume: 10, anno: 2001,
pagine: 139 - 155
SICI:
1354-3784(200101)10:1<139:VHANLA>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
SPONTANEOUSLY HYPERTENSIVE RATS; FOCAL CEREBRAL-ISCHEMIA; CALCIUM-ANTAGONIST AE0047; CHOLESTEROL-FED RABBITS; CHANNEL BLOCKER AE0047; RENAL-FUNCTION; MANIDIPINE HYDROCHLORIDE; POSSIBLE MECHANISM; ANESTHETIZED DOGS; ENTRY BLOCKER;
Keywords:
atherosclerosis; calcium channel blocker; cerebrovascular disease; hypertension; renal function;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
79
Recensione:
Indirizzi per estratti:
Indirizzo: Matsumura, Y Osaka Univ Pharmaceut Sci, Dept Pharmacol, 4-20-1 Nasahara, Takatsuki, Osaka 5691094, Japan Osaka Univ Pharmaceut Sci 4-20-1 Nasahara Takatsuki Osaka Japan 5691094
Citazione:
Y. Matsumura e K. Hayashi, "Vatanidipine hydrochloride: a new long-lasting antihypertensive agent", EXPERT OP I, 10(1), 2001, pp. 139-155

Abstract

Vatanidipine is a novel dihydropyridine (DHP)-type calcium channel blockerwith slow-onset pharmacological actions, which are probably due to both its slow uptake into vascular tissues and resistance in its approach to the calcium channel binding site. Vatanidipine once incorporated into vascular tissues is not easily released, even by repeated washing, thus resulting in a long-lasting action of the agent. A slow-onset and long-lasting hypotensive action was observed in various experimental hypertensive models. Clinical trials using human subjects with essential hypertension indicated that vatanidipine exerts an antihypertensive effect with a slow onset and long duration. In spite of its potent hypotensive effect, the incidence of adverse effects by vatanidipine administration has been reported to be lower than that in cases of nitrendipine. In addition to its vasodilatory effects, vatanidipine efficiently suppressed noradrenaline release from sympathetic nerve endings, thus suggesting this agent exhibits a beneficial effect in the treatment of hypertensive patients, in which the reflex activation of peripheral sympathetic nerves is unfavourable to antihypertensive therapy. In a double-blind study, vatanidipine did not show reflex tachycardia, despite producing a potent and long-lasting hypotensive effect, in contrast to the administration of nitrendipine. In an animal study, vatanidipine exhibited a protective effect against cerebrovascular lesions, through a mechanism independent of its hypotensive effect. In addition, a renoprotective effect wasalso observed in experimental hypertensive models. Ln cholesterol-fed rabbits, vatanidipine exerted an anti-atherosclerotic action, which is probablyattributable to the inhibitory action of the agent on low-density lipoprotein oxidation. In essential hypertensive patients, the plasma levels of cholesterol and triglyceride decreased after vatanidipine treatment, thus suggesting that this agent may have a therapeutic potential in preventing such vascular diseases as atherosclerosis. Taken together, vatanidipine appears to be a novel and useful antihypertensive agent, which can both prevent target-organ damage and reduce cardiovascular morbidity and mortality.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/10/20 alle ore 01:31:17